Guidelines for Complications of Cancer Treatment Vol VIII Part B

PATIENTS AND METHODS: Follow-up study of survivingUK patients with medulloblastoma diagnosed between 1992and 2000 treated according to one or other treatment arm ofthe PNET 3 controlled trial. RESULTS: Seventy three percent of all 147 eligible patientsages 6.6 to 24.3 years were assessed at a mean of 7.2 yearsafter diagnosis. Health status was significantly poorer in thegroup treated in the CSI plus CT arm of the trial than in theCSI alone arm, and there were also trends to poorer outcomesfor behavior and quality of life scores. The CSI plus CT groupwere also significantly more restricted physically and neededmore therapeutic and educational support. Body mass index,stature, and other endocrine outcomes were similar in the twotreatment arms, except for the trend in increased frequency ofmedical induction of puberty in the CSI plus CT group.CONCLUSION: The addition of CT to CSI formedulloblastoma was associated with a significant decreasein health status. The effect of the addition of other CT regimensto CSI on quality of survival should be evaluated.B. Endocrine function1. Long-term neuro-endocrine sequelae after treatmentfor childhood medulloblastoma. Heikens J, MichielsEM, Behrendt H, Endert E, Bakker PJ, Fliers E. Eur JCancer. 1998;34(10):1592-7.The occurrence of neuro-endocrine deficiencies followingcraniospinal irradiation for medulloblastoma is well known,but data concerning the spectrum and prevalence of endocrineabnormalities in adulthood are scarce. We studied endocrinefunction in 20 (median age 25 years) adult subjects, 8-25 years(median 16 years) after therapy. The radiation dose to the wholecranium and spinal axis was 35 +/- 2.6 Gray (mean +/- standarddeviation) with a boost to the posterior fossa of 18 +/- 3.7Gray. 13 subjects had received additional chemotherapy. In362